Bio-Techne (TECH) was downgraded to a Hold Rating at TD Cowen
In a report released today, Kyle Boucher from TD Cowen downgraded Bio-Techne to a Hold, with a price target of $73.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Boucher is a 4-star analyst with an average return of 23.4% and a 90.91% success rate. Boucher covers the Healthcare sector, focusing on stocks such as Bio-Techne, Standard BioTools, and Bruker.
In addition to TD Cowen, Bio-Techne also received a Hold from Citi’s Patrick B Donnelly in a report issued today. However, on June 26, Wells Fargo maintained a Buy rating on Bio-Techne (NASDAQ: TECH).
Based on Bio-Techne’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $311.42 million and a net profit of $51.06 million. In comparison, last year the company earned a revenue of $316.18 million and had a net profit of $22.59 million
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TECH in relation to earlier this year. Last month, Amy E. Herr, a Director at TECH sold 6,636.00 shares for a total of $320,386.08.
Read More on TECH:
